Navigation Links
Stereotaxis Announces Initial Shipments of the Epoch™ Platform to Customers
Date:12/13/2011

ST. LOUIS, Dec. 13, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:   STXS) today announced that the Company has started initial shipments of the Epoch platform, its comprehensive solution for the electrophysiology (EP) lab that is designed to increase efficiency in procedures with a fully-remote, networked robotic and magnetic navigation system.  Initial shipments include system upgrades to the new generation Epoch platform from the Niobe® II navigation system for customers in North America and Europe.  As part of the Epoch upgrades, centers in Europe will also install the Company's Vdrive Duo™ mechanical arm robotic navigation system.  The Vdrive Duo arm allows physicians to remotely manipulate a growing array of devices, such as the loop diagnostic catheter and sheath, while also manipulating the magnetic catheter. 

The Epoch platform is designed to improve efficiency and enhance workflow by allowing the physician to control all aspects of the procedure remotely.  It combines the proven value of remote magnetic catheter control and the efficiency benefits of remote robotic device manipulation with the Vdrive™ mechanical arm.  Additionally, the new Epoch user interface is designed to shorten the learning curve for Stereotaxis' platform, thus addressing the needs of the large commercial market.                                                                                                                           

"The Epoch platform has generated tremendous market excitement since its introduction at the annual Heart Rhythm Society meeting in May," said Michael P. Kaminski, President and CEO of Stereotaxis.  "As expected, the initial wave of commitments is coming from current customers who see the clear benefit to upgrade their system to Epoch.  Additionally, we have experienced a surge in new prospective customers visiting our headquarters to understand how Epoch would fit their EP lab needs.  We are excited about the interest in Epoch from current users and the demand curve for prospective customers, and believe we are poised for strong performance in 2012."

About Stereotaxis             www.stereotaxis.com         www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey Cinema™ Studio then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to attract patients and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. The Vdrive Duo is not cleared for sale in the U.S. and is currently under review by the FDA. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, our continued access to capital and financial resources, including our ability to negotiate financing and lending arrangements on terms that are acceptable, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

 


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis to Present at the Oppenheimer Healthcare Conference on December 13, 2011
2. Stereotaxis Reports Third Quarter Financial Results
3. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
4. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
5. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
6. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
7. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
8. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
9. Stereotaxis to Report Second Quarter 2011 Financial Results and Conduct Conference Call on August 8, 2011
10. Stereotaxis and Biosense Webster Announce New Strategic Collaboration
11. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):